Atrial Fibrillation (AF) is the most common arrhythmia in clinical practice, potentially resulting in the elevated risks of stroke or systemic thromboembolism, myocardial infarction, heart failure, kidney disease and death. Oral anticoagulant therapy such as direct oral anticoagulants (DOACs) and vitamin K antagonists is of vital importance in AF-related stroke prevention. Current AF guidelines recommend that use of direct oral anticoagulants (DOACs) are the first choice in stroke prevention based on the data of four prior DOAC developmental clinical trials. The randomized trial database COMBINE AF study performed a patient-level meta-analysis by including the four remark DOAC trials, which might be the end of the era for data analyses of DOAC trials. However, clinical research for stroke prevention in AF patients with non-cardiovascular co-morbidities (e.g., hyperthyroidism, intracranial haemorrhage, pulmonary disease, cirrhosis, anemia, cancer, dialysis) should be continued to be explored.
In this Research Topic, we would like to create a forum for current advances on the role of oral anticoagulant therapy in AF patients with co-morbidities. Specifically, we’d like to pay attention to non-cardiovascular co-morbidities, such as hyperthyroidism, intracranial haemorrhage, pulmonary disease, cirrhosis, anemia, cancer, dialysis.
We welcome submissions in the following subtopics, but not limited to:
1) Comparisons of different anticoagulant therapy strategies (specifically DOACs versus warfarin) in AF patients with co-morbidities.
2) Age or sex-related differences of oral anticoagulant therapy in the specific AF population.
3) DOAC type or dose choice in AF patients with co-morbidities.
4) Effect of oral anticoagulant therapy in certain conditions (e.g., heart failure, acute myocardial infarction) with new-onset AF or subclinical AF.
5) Association of oral anticoagulant therapy with disease recurrence in AF patients with co-morbidities.
Atrial Fibrillation (AF) is the most common arrhythmia in clinical practice, potentially resulting in the elevated risks of stroke or systemic thromboembolism, myocardial infarction, heart failure, kidney disease and death. Oral anticoagulant therapy such as direct oral anticoagulants (DOACs) and vitamin K antagonists is of vital importance in AF-related stroke prevention. Current AF guidelines recommend that use of direct oral anticoagulants (DOACs) are the first choice in stroke prevention based on the data of four prior DOAC developmental clinical trials. The randomized trial database COMBINE AF study performed a patient-level meta-analysis by including the four remark DOAC trials, which might be the end of the era for data analyses of DOAC trials. However, clinical research for stroke prevention in AF patients with non-cardiovascular co-morbidities (e.g., hyperthyroidism, intracranial haemorrhage, pulmonary disease, cirrhosis, anemia, cancer, dialysis) should be continued to be explored.
In this Research Topic, we would like to create a forum for current advances on the role of oral anticoagulant therapy in AF patients with co-morbidities. Specifically, we’d like to pay attention to non-cardiovascular co-morbidities, such as hyperthyroidism, intracranial haemorrhage, pulmonary disease, cirrhosis, anemia, cancer, dialysis.
We welcome submissions in the following subtopics, but not limited to:
1) Comparisons of different anticoagulant therapy strategies (specifically DOACs versus warfarin) in AF patients with co-morbidities.
2) Age or sex-related differences of oral anticoagulant therapy in the specific AF population.
3) DOAC type or dose choice in AF patients with co-morbidities.
4) Effect of oral anticoagulant therapy in certain conditions (e.g., heart failure, acute myocardial infarction) with new-onset AF or subclinical AF.
5) Association of oral anticoagulant therapy with disease recurrence in AF patients with co-morbidities.
